Immunic Late-stage Program for Lead Asset to Proceed as Planned

Seeking AlphaOct 23 02:06

Immunic Phase 3 MS Study Advances Following Positive Recommendation From Independent Committee | NASDAQ:IMUX

Proactive InvestorsOct 22 21:13

GRI Bio GRI Warrants Exercised; Immunic IMUX Phase 3 IDMC Recommendation

BioPharmCatalystOct 22 20:21

Immunic Shares Advance on Positive Outcome From Interim Analysis of Potential MS Treatment

MT NewswiresOct 22 20:09

EF Hutton Maintains Buy on Immunic, Maintains $17 Price Target

BenzingaOct 22 19:47 · Ratings

Immunic Analyst Ratings

BenzingaOct 22 19:46 · Ratings